Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation

British Journal of Clinical Pharmacology

Volumn 70, Issue 2, 2010, Pages 201-212

  Revilla, Natalia ^a   Martín Suárez, Ana ^a   Pérez, Marta Paz ^b   González, Félix Martín ^b   Fernández De Gatta, María Del Mar ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

AUC(0,24 h): MIC; dosage individualization; intensive care unit; pharmacokinetics pharmacodynamics or PK PD; population pharmacokinetics; vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPUTER PROGRAM; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE REGIMEN; FEMALE; HUMAN; INTENSIVE CARE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 77954471736     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03679.x     Document Type: Article

References (43)

1. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006 42 : 389 391.
2. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996 22 : 387 394.
3. Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997 156 : 196 200. (Pubitemid 27293188)
4. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000 118 : 146 155.
5. Kollef MH. Improving outcomes in the ICU setting: are we effectively using all of the information that is potentially available to us? Chest 1999 115 : 1490 1492.
6. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005 44 : 1009 1034.
7. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998 26 : 1 10 quiz 1-2.
8. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004 43 : 925 942.
9. Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin Pharmacokinet 2008 47 : 147 152.
10. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006 166 : 2138 2144.
11. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006 130 : 947 955.
12. Fernandez de Gatta MM, Revilla N, Calvo MV, Dominguez-Gil A, Sanchez Navarro A. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007 33 : 279 285.
13. Drusano GL, D'Argenio DZ, Preston SL, Barone C, Symonds W, LaFon S, Rogers M, Prince W, Bye A, Bilello JA. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother 2000 44 : 1655 1659.
14. European Society of Clinical Microbiology and Infectious Diseases. The European Committee on Antimicrobial Susceptibility Testing-Eucast online. Available at http://www.eucast.org last accessed 25 February 2008 C, Brendel K, Comets E, Laffont CM, Laveille C, Tranchand B, Mentre F, Lemenuel-Diot A, Girard P. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol 2007 64 : 603 612.
15. Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 2006 31 : 447 454.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985 13 : 818 829.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130 : 461 470.
18. Beal SL, Sheiner LB. NONMEM User's Guides. NONMEM Project Group.
19. Akaike HA. Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 1979 66 : 237 242.
20. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetics model. In : Advanced Methods of Pharmacokinetics An Pharmacodynamic System Analysis, ed. DÀrgenio DZ.
21. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentré F. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated. A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007 46 : 221 234.
22. Vozeh S, Maitre PO, Stanski DR. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm 1990 18 : 161 173.
23. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005 55 : 601 607.
24. Kantzanou M, Tassios PT, Tseleni-Kotsovili A, Legakis NJ, Vatopoulos AC. Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1999 43 : 729 731. (Pubitemid 29231703)
25. Machain L. SimulAr: Montecarlo simulation in Excel online. Available at http://www.simularsoft.com.ar/last accessed 22 November 2007 E, Le Bouquin V, Le Corre P, Kerebel C, Trout H, Feuillu A, Le Verge R, Malledant Y. Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients. Ther Drug Monit 1999 21 : 395 403.
26. Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000 45 : 329 335.
27. DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004 58 : 259 268.
28. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006 42 : 1764 1771.
29. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008 46 (Suppl. 5 S360 7.
30. Buelga DS, Fernández de Gatta M, Herrera EV, Dominguez-Gil A, Garcia MJ. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother 2005 49 : 4934 4941.
31. Staatz CE, Byrne C, Thomson AH. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. Br J Clin Pharmacol 2005 61 : 164 176.
32. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005 60 : 265 275.
33. Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit 1998 20 : 139 148. (Pubitemid 28163195)
34. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984 25 : 433 437.
35. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009 37 : 840 851.
36. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009 63 : 1050 1057.
37. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008 30 : 674 681.
38. Murphy JE, Gillespie DE, Bateman CV. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm 2006 63 : 2365 2370.
39. Fernandez de Gatta MM, Santos Buelga D, Sánchez-Navarro A, Dominguez-Gil A, Garcia MJ. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clin Pharmacokinet 2009 48 : 1 8.
40. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr., Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009 66 : 82 98.
41. Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, Viale P. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continous infusion in the critically ill patients: the Optivanco study. Antimicrob Agents Chemother 2009 53 : 1863 1867.
42. DeRyke CA, Alexander DP. Optimizing vancomycin dosing trough pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp Pharm 2009 44 : 751 765.
43. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008 52 : 1330 1336.